Open AccessObjective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
Author(s) -
Masatoshi Kudo,
Kazuomi Ueshima,
Yasutaka Chiba,
Sadahisa Ogasawara,
Shuntaro Obi,
Namiki Izumi,
Hiroshi Aikata,
Hiroaki Nagano,
Etsuro Hatano,
Yutaka Sasaki,
Keisuke Hino,
Takashi Kumada,
Kazuhide Yamamoto,
Yumiko Imai,
Shouta Iwadou,
Chikara Ogawa,
Takuji Okusaka,
Fumihiko Kanai,
Yasuaki Arai
Publication year - 2019
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000503032
Subject(s) - sorafenib , hepatocellular carcinoma , medicine , proportional hazards model , oncology , gastroenterology , overall survival , response evaluation criteria in solid tumors , subgroup analysis , clinical trial , confidence interval , phases of clinical research
In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between objective response by mRECIST and OS in the sorafenib group, in the combination group, and in all patients in the SILIUS trial.